$5.61 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter

Share on StockTwits

Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to report $5.61 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for ADMA Biologics’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $6.50 million. ADMA Biologics posted sales of $4.73 million during the same quarter last year, which suggests a positive year over year growth rate of 18.6%. The business is expected to report its next quarterly earnings report on Friday, November 2nd.

On average, analysts expect that ADMA Biologics will report full-year sales of $21.03 million for the current year, with estimates ranging from $18.00 million to $22.40 million. For the next fiscal year, analysts expect that the firm will report sales of $55.86 million per share, with estimates ranging from $29.00 million to $111.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover ADMA Biologics.

A number of equities research analysts have recently weighed in on ADMA shares. ValuEngine upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Chardan Capital started coverage on ADMA Biologics in a report on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective for the company. Maxim Group set a $10.00 price objective on ADMA Biologics and gave the company a “buy” rating in a report on Monday, May 14th. Oppenheimer started coverage on ADMA Biologics in a report on Thursday, July 12th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, BidaskClub downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Seven investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $9.50.

In related news, CEO Adam S. Grossman acquired 52,301 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was acquired at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the acquisition, the chief executive officer now owns 32,527 shares of the company’s stock, valued at approximately $155,479.06. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman acquired 20,921 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, with a total value of $100,002.38. Following the acquisition, the director now directly owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Insiders purchased 78,222 shares of company stock valued at $373,901 in the last quarter. 16.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Millennium Management LLC increased its holdings in ADMA Biologics by 254.0% in the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 48,455 shares during the last quarter. BlackRock Inc. increased its holdings in shares of ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 15,115 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of ADMA Biologics in the first quarter worth about $102,000. JPMorgan Chase & Co. bought a new stake in shares of ADMA Biologics in the first quarter worth about $182,000. Finally, Element Capital Management LLC bought a new stake in shares of ADMA Biologics in the first quarter worth about $118,000. Institutional investors and hedge funds own 56.38% of the company’s stock.

ADMA stock opened at $6.85 on Thursday. The firm has a market cap of $296.17 million, a PE ratio of -3.59 and a beta of 2.36. ADMA Biologics has a twelve month low of $2.01 and a twelve month high of $6.93. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: Book Value Of Equity Per Share – BVPS Explained

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply